Please enable Javascript
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Rob Dillard
Rob Dillard is a Medical Writer at AMC Media Group.
Articles by Rob Dillard
Anitocabtagene Autoleucel Effective in Patients With Relapsed, Refractory Multiple Myeloma
Rob Dillard
Myeloma
|
September 18, 2024
Anito-cel showed "robust" efficacy in patients with relapsed or refractory multiple myeloma.
Read More
How Does Multiple Myeloma Remission Affect Heart Attack Outcomes?
Rob Dillard
Myeloma
|
September 18, 2024
Myeloma in remission did not appear to affect myocardial infarction outcomes, but did affect resource utilization.
Read More
Teclistamab Demonstrates Robust Efficacy in Patients With Relapsed or Refractory Multiple Myeloma
Rob Dillard
Myeloma
|
September 18, 2024
The latest data update on teclistamab in multiple myeloma continues to support strong efficacy and durable response.
Read More
Adding Daratumumab to VRd Improves Outcomes in Transplant-Eligible Patients With Newly Diagnosed Myeloma
Rob Dillard
Myeloma
|
September 18, 2024
The addition of daratumumab improved the performance of VRd in patients with newly diagnosed multiple myeloma.
Read More
New or Worsening Anemia Does Not Impact Clinical Benefit of Ruxolitinib in Patients With Myelofibrosis
Rob Dillard
Myelofibrosis
|
September 10, 2024
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Read More
Hemoglobin Improvement Associated With Improved PROs in Myelofibrosis Patients With Anemia
Rob Dillard
Myelofibrosis
|
September 10, 2024
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Read More
Study Analyzes Progression from Essential Thrombocythemia to Myelofibrosis
Rob Dillard
Myelofibrosis
|
September 10, 2024
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Read More
Do Myelofibrosis, Essential Thrombocythemia Patients With CALR Mutations Have Lower Disease Risk?
Rob Dillard
Myelofibrosis
|
September 10, 2024
Patients with MF or ET with CALR or JAK2 mutations carried similar symptom burdens according to prospective data.
Read More
Lenalidomide and Eltrombopag Effective at Treating Low- or Intermediate-Risk Myelodysplastic Syndrome
Rob Dillard
Myelodysplastic Syndromes
|
February 2, 2023
Jesus D. Gonzalez-Lugo, MD, and colleagues, presented the findings at the 2021 ASH Annual Meeting.
Read More
COVID-19 Vaccine Reduced Efficacy in Blood Cancer Patients
Rob Dillard
Chronic Lymphocytic Leukemia
|
February 2, 2023
The results of two studies indicate that the mRNA COVID-19 vaccine may have attenuated efficacy in people with CLL.
Read More
Evaluating Molecular Mutations in AML Patients from Turkey
Rob Dillard
Acute Myeloid Leukemia
|
February 2, 2023
Certain genetic mutations may play a role in the etiology of acute myeloid leukemia.
Read More
Influence of TBI Dose on Idiopathic Pneumonia Syndrome in Pediatric Leukemia
Rob Dillard
Acute Lymphoblastic Leukemia
|
February 2, 2023
A study evaluated the relationship between TBI and development of IPS in patients undergoing transplant for acute leukemia.
Read More
CircRNF220 Regulates Cell Growth and is Linked with Relapse in Pediatric AML
Rob Dillard
Acute Myeloid Leukemia
|
February 2, 2023
Circular RNAs may serve as an efficient and specific diagnosis tool of pediatric acute myeloid leukemia.
Read More
Renal Dysfunction in Pediatric Acute Leukemia
Rob Dillard
Acute Lymphoblastic Leukemia
|
February 2, 2023
A study was conducted to elucidate the effect of TBI parameters and peri-HCT factors on late renal dysfunction.
Read More
Racial and Ethnic Differences in Mortality Among Hispanics Diagnosed With Follicular Lymphoma and CLL
Rob Dillard
Chronic Lymphocytic Leukemia
|
February 2, 2023
Research indicates that Hispanic patients with DLBCL have better survival than non-Hispanic White.
Read More
Assessing the Impact of COVID-19 Countermeasures in Korean Patients with Lymphoma and Multiple Myeloma
Rob Dillard
Myeloma
|
November 14, 2022
Researchers sought to discern the effect of COVID-19 countermeasures on treatment outcomes in a patient population receiving ...
Read More
Residence in a Hispanic Enclave Linked with Worse Overall Survival Among Children with ALL
Rob Dillard
Acute Lymphoblastic Leukemia
|
February 2, 2023
Hispanic children with ALL have worse overall survival.
Read More
Association Between Kidney Function and Multiple Myeloma in a South Korean Population
Rob Dillard
Myeloma
|
November 14, 2022
Researchers of a study investigated the relationship between chronic kidney disease and multiple myeloma (MM) in a South ...
Read More
Socioeconomic Status and Race are Factors in Multiple Myeloma Interventions
Rob Dillard
Myeloma
|
November 14, 2022
Socioeconomic status (SES) and race/ethnicity should be considered when planning multiple myeloma (MM) interventions, ...
Read More
Socioeconomic Factors in Multiple Myeloma
Rob Dillard
Myeloma
|
November 14, 2022
Socioeconomic factors play a big role in multiple myeloma (MM) disparities, according to a study published in ...
Read More
Load More